# Metlife Inc: overview

MET · NYSE · CIK 1099219 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/met.md) · [Financials](/companies/met/financials.md) · [Filings](/companies/met/filings.md) · [Insiders](/companies/met/insiders.md)

Latest reported revenue: [$724.0m](/filings/0001099219-26-000050.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001099219-26-000050).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [554](/filings/0001099219-25-000230.md) | [556 d](/filings/0001099219-26-000013.md) | [611](/filings/0001099219-26-000035.md) | [604](/filings/0001099219-26-000050.md) | [621](/filings/0001099219-25-000230.md) | [600 d](/filings/0001099219-26-000013.md) | [734](/filings/0001099219-26-000035.md) | [724](/filings/0001099219-26-000050.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [260.3%](/filings/0001099219-25-000230.md) | [268.2% d](/filings/0001099219-26-000013.md) | [231.6%](/filings/0001099219-26-000035.md) | [230.6%](/filings/0001099219-26-000050.md) | [265.7%](/filings/0001099219-25-000230.md) | [279.8% d](/filings/0001099219-26-000013.md) | [222.2%](/filings/0001099219-26-000035.md) | [221.5%](/filings/0001099219-26-000050.md) |
| Net margin | % | [242.2%](/filings/0001099219-25-000230.md) | [228.6% d](/filings/0001099219-26-000013.md) | [154.7%](/filings/0001099219-26-000035.md) | [120.7%](/filings/0001099219-26-000050.md) | [144.3%](/filings/0001099219-25-000230.md) | [134.8% d](/filings/0001099219-26-000013.md) | [161.4%](/filings/0001099219-26-000035.md) | [101.7%](/filings/0001099219-26-000050.md) |
| Diluted EPS | $ per share | [1.81](/filings/0001099219-25-000230.md) | not reported | [1.28](/filings/0001099219-26-000035.md) | [1.03](/filings/0001099219-26-000050.md) | [1.22](/filings/0001099219-25-000230.md) | not reported | [1.74](/filings/0001099219-26-000035.md) | [1.09](/filings/0001099219-26-000050.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,074](/filings/0001099219-24-000035.md) | [2,110](/filings/0001099219-25-000044.md) | [2,229](/filings/0001099219-26-000013.md) | [2,245](/filings/0001099219-26-000013.md) | [2,436](/filings/0001099219-26-000013.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | [283.3%](/filings/0001099219-25-000044.md) | [256.8%](/filings/0001099219-26-000013.md) | [267.1%](/filings/0001099219-26-000013.md) | [251.9%](/filings/0001099219-26-000013.md) |
| Net margin | % | [330.5%](/filings/0001099219-24-000035.md) | [250.4%](/filings/0001099219-25-000044.md) | [70.8%](/filings/0001099219-26-000013.md) | [197.1%](/filings/0001099219-26-000013.md) | [138.7%](/filings/0001099219-26-000013.md) |
| Diluted EPS | $ per share | [7.65](/filings/0001099219-24-000035.md) | [6.30](/filings/0001099219-25-000044.md) | [1.81](/filings/0001099219-26-000013.md) | [5.94](/filings/0001099219-26-000013.md) | [4.71](/filings/0001099219-26-000013.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/met/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $4.38bn | 51,786,925 |  | Added +363,045 |
| [Dodge & Cox](/funds/200217.md) | 2026-06-30 | $4.10bn | 48,431,150 |  | Reduced −2,683,626 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.00bn | 35,483,789 |  | Reduced −373,028 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $2.54bn | 30,031,431 |  | Reduced −782,010 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $2.14bn | 25,336,999 |  | Added +116,610 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.14bn | 13,309,884 |  | Added +65,608 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.06bn | 12,532,097 |  | Added +1,411,340 |
| [PZENA INVESTMENT MANAGEMENT LLC](/funds/1027796.md) | 2026-06-30 | $941.8m | 11,130,983 |  | Reduced −172,836 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $608.5m | 7,190,673 |  | Added +67,509 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $586.3m | 6,929,794 |  | Added +10,431 |

## Recent filings

[All 2,947 filings](/companies/met/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-24 | 20:06 ET | [8-K](/filings/0001099219-26-000055.md) | 7.01 Regulation FD disclosure | 0001099219-26-000055 |
| 2026-08-17 | 20:30 ET | [8-K](/filings/0001099219-26-000052.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001099219-26-000052 |
| 2026-08-06 | 20:56 ET | [SCHEDULE 13D/A](/filings/0001193125-26-338366.md) | Ownership report, active investor, amended | 0001193125-26-338366 |
| 2026-08-06 | 20:32 ET | [10-Q](/filings/0001099219-26-000050.md) | Quarterly report, period 2026-06-30 | 0001099219-26-000050 |
| 2026-08-05 | 20:31 ET | [8-K](/filings/0001099219-26-000048.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001099219-26-000048 |
| 2026-06-29 | 10:27 ET | [8-K](/filings/0001099219-26-000045.md) | 7.01 Regulation FD disclosure | 0001099219-26-000045 |
| 2026-06-22 | 20:21 ET | [8-K](/filings/0001099219-26-000041.md) | 5.07 Shareholder vote results | 0001099219-26-000041 |
| 2026-05-15 | 20:18 ET | [8-K](/filings/0001099219-26-000037.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001099219-26-000037 |
| 2026-05-07 | 21:42 ET | [SCHEDULE 13D/A](/filings/0001193125-26-212514.md) | Ownership report, active investor, amended | 0001193125-26-212514 |
| 2026-05-07 | 21:09 ET | [10-Q](/filings/0001099219-26-000035.md) | Quarterly report, period 2026-03-31 | 0001099219-26-000035 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001099219-26-000013.md), filed Feb 19, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ec02f6b4-65fc-4c5a-b87a-d33269d0f047)

## About the filer

- CIK: 1099219
- Tickers: MET, MET-PA, MET-PE, MET-PF
- Exchange: NYSE
- SIC code: 6311 Life Insurance
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.